ReviewClinical advances in hematology & oncology : H&O2021
DA-R-EPOCH vs R-CHOP in DLBCL: How do we choose?
Review in Clinical advances in hematology & oncology : H&O, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 26 citations in OpenAlex.
- Concurrent thyroid and abdominal diffuse large B-cell lymphoma arising in the milieu of chronic fibrosing thyroiditis.JCEM case reports · 2026Article
- Late-Onset Neutropenia and Hypogammaglobulinemia After Dose-Adjusted R-EPOCH in Unfavorable Diffuse Large B-Cell Lymphoma.Life (Basel, Switzerland) · 2026Article
- Predictive value of natural killer (NK) cells in bone marrow for relapse in diffuse large B cell lymphoma: integrating antibody-dependent cell-mediated cytotoxicity (ADCC)-based immunotherapy.Cancer immunology, immunotherapy : CII · 2026Article
- A Phase 1 Dose-Escalation, Food Effect, and Drug-Drug Interaction Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the MALT1 Inhibitor, SGR-1505, in Healthy Volunteers.Clinical pharmacology in drug development · 2026Article
- A study comparing the efficacy of R-CHOP and R-DA-EPOCH regimens in young, high-risk treatment-naïve diffuse large B-cell lymphoma patients: a multicenter retrospective analysis.American journal of cancer research · 2026Article
- CD20 targeted nanomedicine for GCB-diffuse large B-cell lymphoma through synergistic effects of apoptosis and ferroptosis.Materials today. Bio · 2025Article
- Article
- What We Know and Do Not Yet Know About the Canine Model of Lymphoma in Human Medicine-The Current State of Knowledge.Cancers · 2025Review
- Efficacy and safety of BTK inhibitors in Richter's transformation: a systematic review of clinical evidence.Frontiers in oncology · 2025Review
- DA-R-EPOCH May Mitigate the Adverse Prognostic Implication of the Diagnosis-to-Treatment Interval (DTI) in Large B-Cell Lymphomas.Clinical lymphoma, myeloma & leukemia · 2025Article
- A case report of surgery-radiotherapy-chemotherapy cured primary diffuse large B-cell lymphoma of the central nervous system associated with HIV infection.Diagnostic pathology · 2024Article
- Prognostic stratification in DLBCL patients with aberrant MYC gene.British journal of haematology · 2024Article
- Uncommon presentation of diffuse large B-cell lymphoma: oral and pulmonary involvements in a young patient: a case report.Journal of medical case reports · 2024Article
- Outcomes of Rituximab-abbs versus Rituximab in Patients with Diffuse Large B-Cell Lymphoma in a Noninferiority Study.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2024Article
- Epidemiology and Real-World Treatment of Incident Diffuse Large B-cell Lymphoma (DLBCL): A German Claims Data Analysis.Oncology and therapy · 2024Article
- Diffuse Large B-cell Lymphoma Presenting as Bronchial Mass.Journal of bronchology & interventional pulmonology · 2024Article
- Acute Pancreatitis Revealing a Diagnosis of Diffuse Large B-Cell Lymphoma.ACG case reports journal · 2024Article
- Development and validation of a novel prognostic nomogram for advanced diffuse large B cell lymphoma.Clinical and experimental medicine · 2024Article
- The Efficacy of Bepotastine Besilate Compared With Hydroxyzine Pamoate for Preventing Infusion Reactions to the First Dose of Rituximab in Patients With Non-Hodgkin Lymphoma: Protocol for a Phase II, Double-Blind, Multicenter Randomized Trial.JMIR research protocols · 2024Article
- A Case of Gastrointestinal Coccidiomycosis With Bowel Perforation Secondary to Relapsing DLBCL.Journal of community hospital internal medicine perspectives · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The emerging molecular and prognostic characterization of diffuse large B-cell lymphoma (DLBCL) has challenged the rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) treatment paradigm in recent years, with the identification of several DLBCL subtypes associated with significantly inferior survival after standard R-CHOP therapy. Efforts to improve upon the R-CHOP backbone have included dose intensification as well as the addition of new agents; the infusional dose-adjusted rituximab, etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin (DA-R-EPOCH) regimen has been identified as a potential replacement for R-CHOP in high-risk DLBCL. In this review, we provide a historical perspective on the R-CHOP and DA-R-EPOCH regimens and summarize the clinical trial literature regarding the efficacy of each regimen in various risk groups of DLBCL. Further, we propose clinical management scenarios in which DA-R-EPOCH may be preferred, including some for patient populations in which the use of R-CHOP vs DA-R-EPOCH is controversial.
Indexed as
Identifiers
34807015PMC9036549W3215319177What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.